targeted therapy – Page 2

Harnessing Exosomes in Neurodegenerative Diseases: Therapeutic Promise and Modification Techniques

By MedXY 08/20/2025

Exosomes, nanoscale vesicles capable of crossing the blood–brain barrier, hold significant potential as targeted therapeutic agents and diagnostic markers in neurodegenerative diseases. Advances in genetic, chemical, and nanomaterial modifications enhance their targeting, representing a promising frontier for treatment.

Clinical Updates news Oncology Specialties

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

By MedXY 08/03/2025

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.

Clinical Updates news

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

By MedXY 08/03/2025

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.

news Oncology Specialties

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates news Oncology Specialties

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Clinical Updates news Oncology Specialties

EMA Recommends Voranigo for IDH-Mutant Grade 2 Glioma: A New Era in Targeted Brain Tumor Therapy

By MedXY 07/30/2025

The EMA’s CHMP recommends Voranigo, a dual IDH1/2 inhibitor, for grade 2 IDH-mutant gliomas, based on phase 3 INDIGO trial results demonstrating significant improvement in progression-free survival and delayed need for further therapy.